Hepatitis B virus hijacks TSG101 to facilitate egress via multiple vesicle bodies

PLoS Pathog. 2023 May 24;19(5):e1011382. doi: 10.1371/journal.ppat.1011382. eCollection 2023 May.

Abstract

Hepatitis B virus (HBV) chronically infects 296 million individuals and there is no cure. As an important step of viral life cycle, the mechanisms of HBV egress remain poorly elucidated. With proteomic approach to identify capsid protein (HBc) associated host factors and siRNA screen, we uncovered tumor susceptibility gene 101 (TSG101). Knockdown of TSG101 in HBV-producing cells, HBV-infected cells and HBV transgenic mice suppressed HBV release. Co-immunoprecipitation and site mutagenesis revealed that VFND motif in TSG101 and Lys-96 ubiquitination in HBc were essential for TSG101-HBc interaction. In vitro ubiquitination experiment demonstrated that UbcH6 and NEDD4 were potential E2 ubiquitin-conjugating enzyme and E3 ligase that catalyzed HBc ubiquitination, respectively. PPAY motif in HBc and Cys-867 in NEDD4 were required for HBc ubiquitination, TSG101-HBc interaction and HBV egress. Transmission electron microscopy confirmed that TSG101 or NEDD4 knockdown reduces HBV particles count in multivesicular bodies (MVBs). Our work indicates that TSG101 recognition for NEDD4 ubiquitylated HBc is critical for MVBs mediated HBV egress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • DNA-Binding Proteins / genetics
  • Hepatitis B virus* / genetics
  • Mice
  • Mice, Transgenic
  • Proteomics*
  • Transcription Factors / genetics

Substances

  • Tsg101 protein
  • Transcription Factors
  • DNA-Binding Proteins

Grants and funding

This work was supported by the National Natural Science Foundation of China (project no. 81971936 to YX), Hubei Province’s Outstanding Medical Academic Leader Program (to YX), Foundation for Innovative Research Groups of the Natural Science Foundation of Hubei (project no. 2020CFA015 to YX), the Fundamental Research Funds for the Central Universities (project no. 2042022kf1215 to XC and 2042021gf0013 to YX) and Basic and Clinical Medical Research Joint Fund of Zhongnan Hospital, Wuhan University (to YX). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.